chen, chenyan – page 15 – eisai china lnc.-爱游戏app官网入口

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced the first results for metastatic endometrial carcinoma obtained from a phase ib/ii study (study 111) of its in-house developed multi-kinase inhibitor lenvatinib mesylate (product names: lenvima® / kisplyx®, “lenvatinib”) in combination with the msd (known as merck & co., inc, kenilworth, nj, usa in the united states and canada) anti-pd-1 antibody pembrolizumab (brand name: keytruda®*), during a presentation at the 53rd annual meeting of the american society of clinical oncology (asco), taking place in chicago, the united states. the two companies are collaborating to develop this combination therapy. study 111 is being conducted to evaluate the activity of the lenvatinib/pembrolizumab combination in select solid tumors.

on april 19, 2017, eisai china inc. (hereinafter referred to as: eisai (china)) was invited to attend the “health to countryside” activity held in yudu county, jiangxi province by the national committee for education, science, culture, health and sports of chinese people’s political consultative conference (cppcc), and donated medicines worth rmb540,000 yuan to the local hospitals. according to the statistics, eisai (china), practicing the philosophy of hhc (human health care) all along, donated medicines worth rmb450,000, rmb490,000, rmb500,000 and rmb540,000 respectively to this activity from the year 2014 to 2017, with the total worth of medicines reaching up to rmb1.98 million yuan.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) and meiji seika pharma co., ltd. (headquarters: tokyo; ceo: daikichiro kobayashi, “meiji”) announced today that they have entered into a license agreement for the commercialization of safinamide (development code: me2125) for the treatment of parkinson’s disease in japan and asia. safinamide is currently under clinical development by meiji in japan.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai” ) announced today that the german federal joint committee (g-ba) has confirmed the additional benefit of in-house developed anticancer agent kisplyx® (lenvatinib mesylate) in combination with everolimus for the treatment of advanced renal cell carcinoma (rcc) compared to everolimus alone in its assessment for insurance reimbursement. based on this additional benefit assessment, price negotiations with the head association of german sick funds (gkv-sv) will be conducted, and a reimbursement price has to be agreed. 

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito) announced today that, in association with its u.s. pharmaceutical subsidiary eisai inc. (collectively, “eisai”), it has reached an agreement with arena pharmaceuticals, inc. (headquarters: california, united states, president and ceo: amit d. munshi) to revise the november 2013 marketing and supply agreement it concluded with arena’s wholly owned subsidiary, arena pharmaceuticals gmbh (collectively, “arena”), for the chronic weight management treatment lorcaserin hydrochloride (generic name, u.s. brand name: belviq® / belviq xr®, “belviq”). under the new agreement, eisai acquires all of arena’s rights to develop and market belviq.